Want to see JP:4571 full AI Analyst Report?
Top Page
NanoCarrier Co., Ltd.
(4571)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥78.00
▼(-41.79% Downside)
Action:Reiterated
Date:10/09/26
The score is held down primarily by weak financial performance—recurring deep losses and negative operating cash flow despite a 2026 revenue rebound and high gross margins. Technicals further pressure the score due to a clear downtrend and negative momentum, even though indicators suggest the stock is oversold. Valuation is also constrained because the company is unprofitable (negative P/E) and has no provided dividend yield.
Positive Factors
Revenue Rebound
The sharp 2026 revenue rebound indicates renewed commercial activity after several years of declines. If sustained, stronger sales can broaden the company’s partnering and licensing base, improve operating leverage, and provide a larger platform for advancing its nanomedicine pipeline.
Negative Factors
Persistent Deep Losses
Persistent and exceptionally deep losses show that the business remains far from break-even despite the 2026 revenue recovery. Continued losses can erode equity, require repeated financing, and make future operating performance dependent on successful development or partnering outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The sharp 2026 revenue rebound indicates renewed commercial activity after several years of declines. If sustained, stronger sales can broaden the company’s partnering and licensing base, improve operating leverage, and provide a larger platform for advancing its nanomedicine pipeline.
Read all positive factors
NanoCarrier Co., Ltd. (4571) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.36B
Dividend YieldN/A
Average Volume (3M)377.03K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth74.24%
EPS Growth-7.78%
CountryJP
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-13.45
Shares Outstanding90,945,460
10 Day Avg. Volume552,500
30 Day Avg. Volume377,026
Financial Highlights & Ratios
PEG Ratio-1.32
Price to Book (P/B)3.10
Price to Sales (P/S)63.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NanoCarrier Co., Ltd. Business Overview & Revenue Model
Company Description
NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological...
How the Company Makes Money
NanoCarrier primarily makes money through (1) collaboration and licensing arrangements for its drug delivery technology and development-stage drug candidates, and (2) payments tied to the progress and commercialization of partnered products. Under...
NanoCarrier Co., Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 202.50M | 174.50M | 108.52M | 135.51M | 202.19M | 264.03M |
| Gross Profit | 179.88M | 153.29M | 78.17M | 110.96M | 159.60M | 220.88M |
| EBITDA | -1.00B | -892.12M | -832.57M | -776.41M | -1.30B | -1.87B |
| Net Income | -1.02B | -943.88M | -835.38M | -780.00M | -1.31B | -1.88B |
Balance Sheet | ||||||
| Total Assets | 5.24B | 5.91B | 4.00B | 5.07B | 5.78B | 7.14B |
| Cash, Cash Equivalents and Short-Term Investments | 4.22B | 4.91B | 3.51B | 4.28B | 4.44B | 5.95B |
| Total Debt | 1.20B | 1.60B | 540.24M | 1.11B | 1.11B | 1.15B |
| Total Liabilities | 1.92B | 2.34B | 1.26B | 1.65B | 1.53B | 1.57B |
| Stockholders Equity | 3.31B | 3.57B | 2.74B | 3.42B | 4.25B | 5.57B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 0.00 | 0.00 | -585.08M | -1.09B | -1.76B |
| Operating Cash Flow | 0.00 | -816.67M | -401.62M | -585.08M | -1.09B | -1.75B |
| Investing Cash Flow | 0.00 | 2.26B | 587.53M | 793.01M | 1.21B | -244.13M |
| Financing Cash Flow | 0.00 | 2.22B | -568.77M | 3.73M | 32.20M | 1.15B |
NanoCarrier Co., Ltd. Technical Analysis
Negative
134.00
Price Trends
99.98
Negative
103.86
Negative
127.41
Negative
Market Momentum
-2.97
Positive
21.78
Positive
5.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Negative. The current price of 134 is above the 20-day moving average (MA) of 97.20, above the 50-day MA of 99.98, and above the 200-day MA of 127.41, indicating a bearish trend. The MACD of -2.97 indicates Positive momentum. The RSI at 21.78 is Positive, neither overbought nor oversold. The STOCH value of 5.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4571.
NanoCarrier Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥181.86B | -108.62 | ― | ― | 1662.38% | 42.86% | |
49 Neutral | ¥7.86B | -7.17 | ― | ― | -19.99% | 16.36% | |
45 Neutral | ¥8.16B | -8.05 | -42.79% | ― | -8.58% | 19.03% | |
44 Neutral | ¥14.22B | -15.83 | ― | ― | -67.40% | -524.23% | |
43 Neutral | ¥7.36B | -5.87 | -33.61% | ― | 74.24% | -7.78% | |
43 Neutral | ¥13.78B | -3.57 | -163.39% | ― | 35.28% | 90.12% |
* Healthcare Sector Average
JP:4571
NanoCarrier Co., Ltd.
79.00
-109.00
-57.98%
JP:4563
AnGes
34.00
-52.00
-60.47%
JP:4564
OncoTherapy Science
19.00
-3.00
-13.64%
JP:4583
Chiome Bioscience Inc.
94.00
-36.00
-27.69%
JP:4588
Oncolys BioPharma, Inc.
5,970.00
5,187.00
662.45%
JP:4888
STELLA PHARMA CORPORATION
394.00
36.00
10.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.